Results 91 to 100 of about 342 (145)

Correlation of the severity of atopic dermatitis with laboratory criteria and more common side effects in patients receiving biologic therapy

, 2021
Mērķis: Izpētīt un salīdzināt visbiežākās blaknes nemolizumab un lebrikizumab medikamentiem. Izpētīt laboratorisko rādītāju korelāciju ar AD smaguma pakāpi.Uzdevumi: Noteikt korelatīvas sakarības starp EASI, IgE, eozinofīliem leikocītiem, neitrofīliem ...
Konohina, Aleksandra
core  

Tralokinumab as a cost-saving treatment option for adults and adolescents with moderate-to-severe atopic dermatitis enrolled in US health insurance plans: a budget impact analysis

Journal of Comparative Effectiveness Research
Background: Atopic dermatitis (AD) is a chronic and burdensome condition that causes intense itching and painful skin lesions and affects around 10% of adults and adolescents across the US.
Reece Grindley, Linnea Houde, Aseel Bin Sawad, Sanjeev Balu, Shannon Schneider   +4 more
doaj   +1 more source

673 - Efficacy of nemolizumab in different subgroups of patients with prurigo nodularis in two randomized, placebo-controlled phase 3 trials

Introduction It is unknown whether baseline demographics and disease characteristics have an influence on efficacy and safety of nemolizumab in adults with moderate-to-severe prurigo nodularis (PN). Objectives To report safety and efficacy of nemolizumab
Gharib, Rola, Kwatra, Shawn G, Piketty, Christophe, Chen, Xiaoxiao, Jabbar Lopez, Zarif K, Ständer, Sonja, Metz, Martin, Sundaram, Hema, Pink, Andrew E, Yosipovitch, Gil, Noda, Aliene   +10 more
core   +1 more source

Therapeutic Targeting of Interleukin-31 and Molecular Detection of c-KIT Mutations in Cutaneous Mast Cell Disorders: Supplementary Figure

Box plot demonstrating change in PP-NRS in 18 patients with recalcitrant itch with MCD (17 patients with symptomatic dermatographia and 1 patient with cutaneous mastocytosis), following initiation of nemolizumab.
Dulai, Ajay
core   +1 more source

Patients\u27 Experiences of Atopic Dermatitis and Nemolizumab Treatment: An In-Trial Interview Study Embedded in a Phase 3 Clinical Trial (ARCADIA)

BACKGROUND: Patients with atopic dermatitis (AD) often experience a multitude of interrelated symptoms and impacts linked to the cardinal symptom of itch.
Puelles, Jorge, Silverberg, Jonathan I, Chambenoit, Olivier, Piketty, Christophe, Rodriguez, Danielle, Dias Barbosa, Carla, Subramanian, Ram, Filipenko, Dina, Jack, Katrin   +8 more
core   +1 more source

Nemolizumab for treatment of lichen amyloidosis

JAAD Case Reports
Nakagawa, Seitaro, Ueda-Hayakawa, Ikuko, Fujimoto, Manabu   +2 more
openaire   +2 more sources

Nemolizumab-induced psoriasiform dermatitis

JAAD Case Reports
Absil, Gilles, Collins, Patrick, Colleye, Orphal, Dezfoulian, Bita, Nikkels, Arjen F.   +4 more
openaire   +2 more sources

Nemolizumab for the treatment of refractory primary localized cutaneous amyloidosis in a nonatopic patient

JAAD Case Reports
Gabriela Soto-Canetti, MPH, Jiwon Park, BA, Avi Bitterman, MD, Jordan Talia, MD   +3 more
doaj   +1 more source

Trastuzumab-associated prurigo nodularis successfully treated with nemolizumab: A case report

JAAD Case Reports
Ryan Chen, BA, Michelle S. Lee, MD, Ashleigh Eberly Puleo, PA-C, Arshna Qureshi, MBBS, Alvaro C. Laga, MD, MMSc, Vinod E. Nambudiri, MD, MBA, MPH, EdM   +5 more
doaj   +1 more source

Correction: Safety and efficacy of nemolizumab for patients with pruritus: a systematic review and meta-regression analysis of randomized controlled trial

Frontiers in Immunology
Junqin Liang, Fengxia Hu, Maoli Dan, Yingbing Sang, Kailibinuer Abulikemu, Qian Wang, Yongzhen Hong, Xiaojing Kang   +7 more
doaj   +1 more source